

CURRICULUM VITAE

Personal history

NAME: Massimo Mosconi, MD

HOME ADDRESS: Via Leonardo da Vinci, 84
Abbiategrosso (Milano)(Italy) 20181
tel. 347/6473556

OFFICE ADDRESS: European Institute of Oncology
Melanoma and muscle cutaneous sarcoma division
Via Ripamonti 435, 20141 Milano
E-Mail: massimo.mosconi@ieo.it

DATE OF BIRTH: July 12, 1969

MARITAL STATUS: Married

MILITARY: 1995-96 Italian Army
General Medical Officer
Central Headquarters, Cuneo (Italy)

Academic history

EDUCATION: 1988-95 Medical School:
University of Pavia
Pavia, Italy
March / 95 Graduated Medical Doctor

RESIDENCY: 1996 –01 University of Pavia
Department of Dermatology and Venereology
Dermatology residency

PROFESSIONAL ORGANIZATIONS: 2001 to present Italian Association of Dermatology and Venereology
Associate member
IMI- Italian Melanoma Intergroup – Associate member

HOSPITAL

APPOINTMENTS: Nov./2001 to European Institute of Oncology (Milan - Italy)
Present Senior Assistant- Melanoma Division

Sub-investigator in the following protocols:

“ A phase III randomized double-blind trial of immunotherapy with a polyvalent melanoma vaccine, CancerVax vaccine plus BCG versus placebo plus BCG as a post-surgical treatment for stage III melanoma”

“ A phase III randomized double-blind trial of immunotherapy with a polyvalent melanoma vaccine, CancerVax vaccine plus BCG versus placebo plus BCG as a post-surgical treatment for stage IV melanoma”

“ Post-operative adjuvant ganglioside GM2-KLH/QS-21 vaccination treatment vs observation after resection of primary cutaneous melanoma. (AJCC stage II, T3-T4N0M0)”

“PEG-intron versus Observation after regional lymph node dissection in AJCC stage III (TxN1-2M0) melanoma patients: a randomized phase III trial EORTC 18991”

“Phase II study of dacarbazine with the anti-vascular endothelial growth factor antibody (Bevacizumab) in patients with unresectable/metastatic melanoma”

“O6-alkylguanine-DNA-alkyltransferase modulation study: Fotemustine plus Temozolomide (phase I/II)”

“Prospective study of the natural history of subjects who were entered in the MMAIT-03-001 and MMAIT-04-001 trials and underwent post-operative therapy with BCG plus placebo or BCG plus Canvaxin™. FARM-MMAITFOLLOW-0606”

“Melanoma treatment patterns and outcomes among patients with unresectable stage III or Stage IV disease: a retrospective longitudinal survey (MELODY study)”

“A randomized, open-label, controlled, multicentre, phase III study in previously untreated patients with unresectable stage IIIc or stage IV melanoma with V600E-BRAF mutation receiving RO5185426 or dacarbazine”

“A Phase III, randomized, double-blinded study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to dabrafenib and placebo as first-line therapy in subjects with unresectable (Stage IIIc) or metastatic (Stage IV) BRAF V600E/K mutation-positive cutaneous Melanoma”

Involved in international clinical trials according to ICH-GCP principles.

2008 training GCP online

PUBLICATIONS:

Bellosta M, Gaviglio M, **Mosconi M**, Cavanna C, Viglio A, Rabbiosi G:
Primary cutaneous cryptococcosis in an HIV-negative patient
European Journal of Dermatology vol.9:224-226, 1999.

Del Forno C, Chiodini R, **Mosconi M**, Parlangei ME, Chiara A:
Hemangiomatose neonatale miliare: presentation d'un cas
Ann Dermatol Venereol vol.126: 1520-1525, 1999.

Testori A, Lazzaro G, Baldini F, Tosti G, **Mosconi M**, Lovati E, Bossi C, Sanvito S, Stanganelli I, Mazzarol G, De Salvo GL, Trifiro G, Biffi R, Bellomi M:
The role of ultrasound of sentinel nodes in the post-operative evaluation of stage I melanoma patient
Melanoma Res. 2005 Jun;15(3):191-8.

Lazzaro G, Lazzari R, Pelosi G, De Pas T, Mariani L, Mazzarol G, Sances D, Tosti G, Baldini F, **Mosconi M**, Tedeschi I, Viale G, Marsiglia H, Chiappa A, Vavassori A, Orecchia R, Testori
A.Pulsed dose-rate perioperative interstitial brachytherapy for soft tissue sarcomas of the extremities and skeletal muscles of the trunk .
Ann Surg Oncol 2005 Oct 3

Trifirò G, Verrecchia F, Soteldo J, Zonta M, Pizzigoni S, Travaini LL, Baldini F, Tosti G, **Mosconi M**, Paganelli G, Mazzarol G, Testori A.
Modification of of lymphoscintigraphic sentinel node identification before and after excisional biopsy of primary cutaneous melanoma.
Melanoma Res 2008;18(6):373-7

Testori A, Baldini F, **Mosconi M**.
Melanoma: trattamento medico e chirurgico
MOPP Medical Oncology Progress & Perspectives – Update 24

A.di Pietro, P. F. Ferrucci, E. Munzone, **M. Mosconi**, S. Gandini, C. Pari, F. Cataldo, F. Verrecchia, F. Nole, A. Testori
Dacarbazine (DTIC) plus bevacizumab (B) combination therapy in chemotherapy (CTh)-naïve advanced melanoma (MM) patients (pts): A phase II study.

Rastrelli M, Soteldo J, Zonta M, Trifirò G, Mazzarol G, Vitali GC, **Mosconi M**, Testori A
Sentinel node biopsy for high-risk cutaneous nonanogenital squamous cell carcinoma: a preliminary result
Eur Surg Res. 2010 Jun 5;44(3-4):204-208.

Testori A, Tosti G, Martinoli C, Spadola G, Cataldo F, Verrecchia F, Baldini F, **Mosconi M**,
Soteldo J, Tedeschi I, Passoni C, Pari C, di Pietro A, Ferrucci PF
Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach
Dermatologic Therapy, Vol. 23, 2010, 651–661

Epithelioid sarcoma of the thumb presenting as a periungual warty lesion: case report and revision of the literature.

Rastrelli M, **Mosconi M**, Tosti G.

J Plast Reconstr Aesthet Surg. 2011 Aug;64(8):e221-2. doi: 10.1016/j.bjps.2011.03.014. Epub 2011 Apr 5.
Review. No abstract available

Sara Gandini, Pier Francesco Ferrucci, Harriet Ann Johansson, Giulio Tosti, Federica Baldini, Giuseppe Spadola, Francesco Cataldo, **Massimo Mosconi**, Maria Di Leo, Bernardo Bonanni, Emilia Cocorocchio, Alessandro Testori;

Italian multicentre phase III trial on vitamin d supplementation for melanoma patients (MelaViD).
Abstract 2013 ASCO Annual Meeting (May 31 - June 4, 2013)

Brain metastasis in melanoma patients: Associations with *BRAF* status and age.

Chiara Martinoli, Emilia Cocorocchio, Sara Gandini, Elisabetta Pennacchioli, Giulio Tosti, Giuseppe Spadola, **Massimo Mosconi**, Federica Baldini, Salvatore Alfieri, Maria Di Leo, Concetta Riviello, Massimo Barberis, Alessandro Testori, Pier Francesco Ferrucci; European Institute of Oncology, Milan, Italy; European Institute of Oncology, Melanoma Division, Milan, Italy; Istituto Europeo di Oncologia, Milano, Italy; Istituto Europeo di Oncologia, Melanoma Division, Milano, Italy; Melanoma and Muscle Cutaneous Sarcoma Division, European Institute of Oncology, Milan, Italy; european institute of oncology, milan, Italy; Melanoma and muscle-cutaneous sarcomas Division, European Institute of Oncology, Milan, Italy. Abstract at 2014 ASCO Annual Meeting (May 30 - June 3, 2014)

Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.

Ferrucci PF, Minchella I, **Mosconi M**, Gandini S, Verrecchia F, Cocorocchio E, Passoni C, Pari C, Testori A, Coco P, Munzone E.
Melanoma Res. 2015 Jun;25(3):239-45.

Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma.

Ferrucci PF, Gandini S, Cocorocchio E, Pala L, Baldini F, **Mosconi M**, Antonini Cappellini GC, Albertazzi E, Martinoli C.
Oncotarget. 2017 Aug 1;8(45):79809-79815. doi: 10.18632/oncotarget.19748. eCollection 2017 Oct 3.

Autorizzo il trattamento dei miei dati personali, nei modi previsti secondo il decreto legislativo del 30 giugno 2003 n° 196.

